{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T03:25:23Z","timestamp":1740108323174,"version":"3.37.3"},"reference-count":59,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2024,1,20]],"date-time":"2024-01-20T00:00:00Z","timestamp":1705708800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,1,20]],"date-time":"2024-01-20T00:00:00Z","timestamp":1705708800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Pharmacol"],"published-print":{"date-parts":[[2024,4]]},"DOI":"10.1007\/s00228-024-03628-2","type":"journal-article","created":{"date-parts":[[2024,1,20]],"date-time":"2024-01-20T11:02:16Z","timestamp":1705748536000},"page":"519-527","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["The lack of head-to-head randomised trials and the consequences for patients and national health service: The case of non-small cell lung cancer"],"prefix":"10.1007","volume":"80","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2411-8743","authenticated-orcid":false,"given":"Ruggero","family":"Lasala","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8705-5837","authenticated-orcid":false,"given":"Alessia","family":"Romagnoli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9105-0745","authenticated-orcid":false,"given":"Fiorenzo","family":"Santoleri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valentina","family":"Isgr\u00f2","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Corrado","family":"Confalonieri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alberto","family":"Costantini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fiorenza","family":"Enrico","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gianluca","family":"Russo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Piera","family":"Polidori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessandra","family":"Di Paolo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesco","family":"Malorgio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giordano","family":"Beretta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Felice","family":"Musicco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,1,20]]},"reference":[{"issue":"3","key":"3628_CR1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL et al (2021) Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 71(3):209\u2013249","journal-title":"CA Cancer J Clin"},{"key":"3628_CR2","doi-asserted-by":"publisher","first-page":"1300","DOI":"10.3389\/fphar.2018.01300","volume":"9","author":"L Falzone","year":"2018","unstructured":"Falzone L, Salomone S, Libra M (2018) Evolution of cancer pharmacological treatments at the turn of the third millennium. Front Pharmacol 9:1300","journal-title":"Front Pharmacol"},{"key":"3628_CR3","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2020.103194","volume":"157","author":"EN Imyanitov","year":"2021","unstructured":"Imyanitov EN, Iyevleva AG, Levchenko EV (2021) Molecular testing and targeted therapy for non-small cell lung cancer: current status and perspectives. Crit Rev Oncol Hematol 157:103194","journal-title":"Crit Rev Oncol Hematol"},{"issue":"8","key":"3628_CR4","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1038\/s41423-020-0488-6","volume":"17","author":"Y Zhang","year":"2020","unstructured":"Zhang Y, Zhang Z (2020) The history and advances in cancer immunotherapy: understanding the characteristics of tumor-infiltrating immune cells and their therapeutic implications. Cell Mol Immunol 17(8):807\u2013821","journal-title":"Cell Mol Immunol"},{"key":"3628_CR5","unstructured":"Ettinger DS, Wood DE, Aisner DL et al (2022) Non-small cell lung cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw 20(5):497\u2013530"},{"issue":"9","key":"3628_CR6","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1016\/j.annonc.2021.06.001","volume":"32","author":"M Reck","year":"2021","unstructured":"Reck M, Carbone DP, Garassino M, Barlesi F (2021) Targeting KRAS in non-small-cell lung cancer: recent progress and new approaches. Annals Oncol 32(9):1101\u20131110","journal-title":"Annals Oncol"},{"key":"3628_CR7","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2020.102105","volume":"90","author":"J Remon","year":"2020","unstructured":"Remon J, Hendriks LEL, Cardona AF, Besse B (2020) EGFR exon 20 insertions in advanced non-small cell lung cancer: a new history begins. Cancer Treat Rev 90:102105","journal-title":"Cancer Treat Rev"},{"issue":"8","key":"3628_CR8","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1200\/JCO.2012.44.5353","volume":"31","author":"AT Shaw","year":"2013","unstructured":"Shaw AT, Engelman JA (2013) ALK in lung cancer: past, present, and future. J Clin Oncol 31(8):1105\u20131111","journal-title":"J Clin Oncol"},{"key":"3628_CR9","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.ctrv.2018.04.006","volume":"66","author":"A Leonetti","year":"2018","unstructured":"Leonetti A, Facchinetti F, Rossi G et al (2018) BRAF in non-small cell lung cancer (NSCLC): pickaxing another brick in the wall. Cancer Treat Rev 66:82\u201394","journal-title":"Cancer Treat Rev"},{"issue":"8","key":"3628_CR10","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1200\/JCO.2011.35.6345","volume":"30","author":"K Bergethon","year":"2012","unstructured":"Bergethon K, Shaw AT, Ou SH et al (2012) ROS1 rearrangements define a unique molecular class of lung cancers. J Clin Oncol 30(8):863\u2013870","journal-title":"J Clin Oncol"},{"issue":"7","key":"3628_CR11","doi-asserted-by":"publisher","first-page":"922","DOI":"10.1158\/2159-8290.CD-19-1446","volume":"10","author":"G Recondo","year":"2020","unstructured":"Recondo G, Che J, Janne PA, Awad MM (2020) Targeting MET dysregulation in cancer. Cancer Discov 10(7):922\u2013934","journal-title":"Cancer Discov"},{"key":"3628_CR12","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.lungcan.2021.09.005","volume":"161","author":"G Harada","year":"2021","unstructured":"Harada G, Santini FC, Wilhelm C, Drilon A (2021) NTRK fusions in lung cancer: from biology to therapy. Lung Cancer 161:108\u2013113","journal-title":"Lung Cancer"},{"issue":"23","key":"3628_CR13","doi-asserted-by":"publisher","first-page":"6102","DOI":"10.1158\/1078-0432.CCR-20-1587","volume":"26","author":"C Belli","year":"2020","unstructured":"Belli C, Anand S, Gainor JF et al (2020) Progresses toward precision medicine in RET-altered solid tumors. Clin Cancer Res 26(23):6102\u20136111","journal-title":"Clin Cancer Res"},{"issue":"8","key":"3628_CR14","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1093\/annonc\/mdz167","volume":"30","author":"J Mazieres","year":"2019","unstructured":"Mazieres J, Drilon A, Lusque A et al (2019) Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry. Annal Oncol 30(8):1321\u20131328","journal-title":"Annal Oncol"},{"issue":"8","key":"3628_CR15","doi-asserted-by":"publisher","first-page":"1138","DOI":"10.1016\/j.jtho.2018.03.035","volume":"13","author":"A Lisberg","year":"2018","unstructured":"Lisberg A, Cummings A, Goldman JW et al (2018) A phase II study of pembrolizumab in EGFR-mutant, PD-L1+, tyrosine kinase inhibitor naive patients with advanced NSCLC. J Thorac Oncol 13(8):1138\u20131145","journal-title":"J Thorac Oncol"},{"issue":"18","key":"3628_CR16","doi-asserted-by":"publisher","first-page":"4585","DOI":"10.1158\/1078-0432.CCR-15-3101","volume":"22","author":"JF Gainor","year":"2016","unstructured":"Gainor JF, Shaw AT, Sequist LV et al (2016) EGFR mutations and ALK rearrangements are associated with low response rates to PD-1 pathway blockade in non-small cell lung cancer: a retrospective analysis. Clin Cancer Res 22(18):4585\u20134593","journal-title":"Clin Cancer Res"},{"issue":"10308","key":"3628_CR17","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.1016\/S0140-6736(21)02098-5","volume":"398","author":"E Felip","year":"2021","unstructured":"Felip E, Altorki N, Zhou C et al (2021) Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB-IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial. Lancet 398(10308):1344\u20131357","journal-title":"Lancet"},{"key":"3628_CR18","doi-asserted-by":"crossref","unstructured":"Akinboro O, Vallejo JJ, Nakajima EC et al (2022) Outcomes of anti\u2013PD-(L)1 therapy with or without chemotherapy (chemo) for first-line (1L) treatment of advanced non\u2013small cell lung cancer (NSCLC) with PD-L1 score \u2265 50%: FDA pooled analysis.\u00a0J Clin Oncol\u00a040(16_suppl):9000\u20139000","DOI":"10.1200\/JCO.2022.40.16_suppl.9000"},{"issue":"6","key":"3628_CR19","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1007\/s00228-020-02850-y","volume":"76","author":"R Lasala","year":"2020","unstructured":"Lasala R, Logreco A, Romagnoli A, Santoleri F, Musicco F, Costantini A (2020) Cancer drugs for solid tumors approved by the EMA since 2014: an overview of pivotal clinical trials. Eur J Clin Pharmacol 76(6):843\u2013850","journal-title":"Eur J Clin Pharmacol"},{"issue":"6","key":"3628_CR20","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2016-011666","volume":"6","author":"AJ Hatswell","year":"2016","unstructured":"Hatswell AJ, Baio G, Berlin JA, Irs A, Freemantle N (2016) Regulatory approval of pharmaceuticals without a randomised controlled study: analysis of EMA and FDA approvals 1999\u20132014. BMJ Open 6(6):e011666","journal-title":"BMJ Open"},{"key":"3628_CR21","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.jclinepi.2019.05.033","volume":"114","author":"A Ladanie","year":"2019","unstructured":"Ladanie A, Speich B, Briel M et al (2019) Single pivotal trials with few corroborating characteristics were used for FDA approval of cancer therapies. J Clin Epidemiol 114:49\u201359","journal-title":"J Clin Epidemiol"},{"issue":"6","key":"3628_CR22","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1001\/jamaoncol.2019.0167","volume":"5","author":"T Hilal","year":"2019","unstructured":"Hilal T, Sonbol MB, Prasad V (2019) Analysis of control arm quality in randomized clinical trials leading to anticancer drug approval by the US Food and Drug Administration. JAMA Oncol 5(6):887\u2013892","journal-title":"JAMA Oncol"},{"key":"3628_CR23","doi-asserted-by":"crossref","unstructured":"Rossi A, Aimar G, Audisio M et al (2023) Analysis of the adequacy of control arms in oncology randomised clinical trials published between 2017 and 2021: a meta-research study.\u00a0Eur J Cancer","DOI":"10.1016\/j.ejca.2023.05.008"},{"issue":"5","key":"3628_CR24","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1001\/jamainternmed.2014.368","volume":"174","author":"G Del Fiol","year":"2014","unstructured":"Del Fiol G, Workman TE, Gorman PN (2014) Clinical questions raised by clinicians at the point of care: a systematic review. JAMA Intern Med 174(5):710\u2013718","journal-title":"JAMA Intern Med"},{"issue":"7521","key":"3628_CR25","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1136\/bmj.331.7521.897","volume":"331","author":"DM Caldwell","year":"2005","unstructured":"Caldwell DM, Ades AE, Higgins JP (2005) Simultaneous comparison of multiple treatments: combining direct and indirect evidence. BMJ 331(7521):897\u2013900","journal-title":"BMJ"},{"issue":"1","key":"3628_CR26","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1111\/bcp.12150","volume":"77","author":"H Kim","year":"2014","unstructured":"Kim H, Gurrin L, Ademi Z, Liew D (2014) Overview of methods for comparing the efficacies of drugs in the absence of head-to-head clinical trial data. Br J Clin Pharmacol 77(1):116\u2013121","journal-title":"Br J Clin Pharmacol"},{"key":"3628_CR27","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.f2914","volume":"346","author":"EJ Mills","year":"2013","unstructured":"Mills EJ, Thorlund K, Ioannidis JP (2013) Demystifying trial networks and network meta-analysis. BMJ 346:f2914","journal-title":"BMJ"},{"issue":"1","key":"3628_CR28","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1056\/NEJMoa1913662","volume":"382","author":"SS Ramalingam","year":"2020","unstructured":"Ramalingam SS, Vansteenkiste J, Planchard D et al (2020) Overall survival with osimertinib in untreated, EGFR-mutated advanced NSCLC. N Engl J Med 382(1):41\u201350","journal-title":"N Engl J Med"},{"issue":"5","key":"3628_CR29","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1016\/S1470-2045(16)30033-X","volume":"17","author":"K Park","year":"2016","unstructured":"Park K, Tan EH, O\u2019Byrne K et al (2016) Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial. Lancet Oncol 17(5):577\u2013589","journal-title":"Lancet Oncol"},{"issue":"11","key":"3628_CR30","doi-asserted-by":"publisher","first-page":"1454","DOI":"10.1016\/S1470-2045(17)30608-3","volume":"18","author":"YL Wu","year":"2017","unstructured":"Wu YL, Cheng Y, Zhou X et al (2017) Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial. Lancet Oncol 18(11):1454\u20131466","journal-title":"Lancet Oncol"},{"issue":"12","key":"3628_CR31","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.1016\/S1470-2045(19)30634-5","volume":"20","author":"K Nakagawa","year":"2019","unstructured":"Nakagawa K, Garon EB, Seto T et al (2019) Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 20(12):1655\u20131669","journal-title":"Lancet Oncol"},{"issue":"11","key":"3628_CR32","doi-asserted-by":"publisher","first-page":"1236","DOI":"10.1016\/S1470-2045(14)70381-X","volume":"15","author":"T Seto","year":"2014","unstructured":"Seto T, Kato T, Nishio M et al (2014) Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): an open-label, randomised, multicentre, phase 2 study. Lancet Oncol 15(11):1236\u20131244","journal-title":"Lancet Oncol"},{"issue":"9","key":"3628_CR33","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1016\/j.jtho.2022.05.008","volume":"17","author":"MC Piccirillo","year":"2022","unstructured":"Piccirillo MC, Bonanno L, Garassino MC et al (2022) Addition of Bevacizumab to Erlotinib as first-line treatment of patients with EGFR-mutated advanced nonsquamous NSCLC: the BEVERLY multicenter randomized phase 3 trial. J Thorac Oncol 17(9):1086\u20131097","journal-title":"J Thorac Oncol"},{"issue":"3","key":"3628_CR34","doi-asserted-by":"publisher","first-page":"e257","DOI":"10.1016\/j.cllc.2021.10.007","volume":"23","author":"N Haratake","year":"2022","unstructured":"Haratake N, Hayashi H, Shimokawa M et al (2022) Phase III clinical trial for the combination of Erlotinib plus Ramucirumab compared with Osimertinib in previously untreated advanced or recurrent non-small cell lung cancer positive for the L858R mutation of EGFR: REVOL858R (WJOG14420L). Clin Lung Cancer 23(3):e257\u2013e263","journal-title":"Clin Lung Cancer"},{"issue":"21","key":"3628_CR35","doi-asserted-by":"publisher","first-page":"2027","DOI":"10.1056\/NEJMoa1810171","volume":"379","author":"DR Camidge","year":"2018","unstructured":"Camidge DR, Kim HR, Ahn MJ et al (2018) Brigatinib versus Crizotinib in ALK-positive non-small-cell lung cancer. N Engl J Med 379(21):2027\u20132039","journal-title":"N Engl J Med"},{"issue":"21","key":"3628_CR36","doi-asserted-by":"publisher","first-page":"2018","DOI":"10.1056\/NEJMoa2027187","volume":"383","author":"AT Shaw","year":"2020","unstructured":"Shaw AT, Bauer TM, de Marinis F et al (2020) First-line Lorlatinib or Crizotinib in advanced ALK-positive lung cancer. N Engl J Med 383(21):2018\u20132029","journal-title":"N Engl J Med"},{"issue":"9","key":"3628_CR37","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1056\/NEJMoa1704795","volume":"377","author":"S Peters","year":"2017","unstructured":"Peters S, Camidge DR, Shaw AT et al (2017) Alectinib versus Crizotinib in untreated ALK-positive non-small-cell lung cancer. N Engl J Med 377(9):829\u2013838","journal-title":"N Engl J Med"},{"issue":"10089","key":"3628_CR38","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/S0140-6736(17)30565-2","volume":"390","author":"T Hida","year":"2017","unstructured":"Hida T, Nokihara H, Kondo M et al (2017) Alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial. Lancet 390(10089):29\u201339","journal-title":"Lancet"},{"issue":"5","key":"3628_CR39","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1016\/S2213-2600(19)30053-0","volume":"7","author":"C Zhou","year":"2019","unstructured":"Zhou C, Kim SW, Reungwetwattana T et al (2019) Alectinib versus crizotinib in untreated Asian patients with anaplastic lymphoma kinase-positive non-small-cell lung cancer (ALESIA): a randomised phase 3 study. Lancet Respir Med 7(5):437\u2013446","journal-title":"Lancet Respir Med"},{"issue":"32","key":"3628_CR40","doi-asserted-by":"publisher","first-page":"4237","DOI":"10.2217\/fon-2021-0608","volume":"17","author":"S Popat","year":"2021","unstructured":"Popat S, Liu G, Lu S, Song G, Ma X, Yang JC (2021) Brigatinib vs alectinib in crizotinib-resistant advanced anaplastic lymphoma kinase-positive non-small-cell lung cancer (ALTA-3). Future Oncol 17(32):4237\u20134247","journal-title":"Future Oncol"},{"key":"3628_CR41","unstructured":"Targeted treatment for ALK positive patients who have previously been treated for non-squamous non-small cell lung cancer. https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT03737994. Published 2023. Updated 14 Apr 2023. Accessed 7 Aug 2023"},{"issue":"24","key":"3628_CR42","doi-asserted-by":"publisher","first-page":"2288","DOI":"10.1056\/NEJMoa1716948","volume":"378","author":"MA Socinski","year":"2018","unstructured":"Socinski MA, Jotte RM, Cappuzzo F et al (2018) Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC. N Engl J Med 378(24):2288\u20132301","journal-title":"N Engl J Med"},{"key":"3628_CR43","doi-asserted-by":"crossref","unstructured":"Frost N, Bleckmann A, Griesinger F et al (2023) Rationale and design of the phase II ANTELOPE study of Atezolizumab, Carboplatin and nab-Paclitaxel vs. Pembrolizumab, platinum and pemetrexed in TTF-1 negative, metastatic lung adenocarcinoma (AIO-TRK-0122). Clin Lung Cancer","DOI":"10.1016\/j.cllc.2023.04.009"},{"key":"3628_CR44","unstructured":"Immune profile selection by fraction of ctDNA in patients with advanced NSCLC treated with immunotherapy (G360-IIT). https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT05715229. Published 2023. Updated 6 Jul 2023. Accessed 2023"},{"key":"3628_CR45","unstructured":"Testing the effects of MK-3475 (Pembrolizumab) with or without the usual chemotherapy treatment for patients 70 years of age and older with advanced non-small cell lung cancer. https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT04533451. Published 2023. Updated 18 Apr 2023. Accessed Aug 2023"},{"issue":"4","key":"3628_CR46","doi-asserted-by":"publisher","first-page":"e285","DOI":"10.1016\/j.cllc.2021.10.012","volume":"23","author":"Y Shiraishi","year":"2022","unstructured":"Shiraishi Y, Hakozaki T, Nomura S et al (2022) A multicenter, randomized phase III study comparing platinum combination chemotherapy plus pembrolizumab with platinum combination chemotherapy plus Nivolumab and Ipilimumab for treatment-naive advanced non-small cell lung cancer without driver gene alterations: JCOG2007 (NIPPON Study). Clin Lung Cancer 23(4):e285\u2013e288","journal-title":"Clin Lung Cancer"},{"key":"3628_CR47","unstructured":"Pemetrexed-free vs. Pemetrexed-based immunochemotherapy in metastatic TTF-1 negative lung adenocarcinoma (ANTELOPE). https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT05689671. Published 2023. Updated 19 Jan 2023. Accessed Aug 2023"},{"key":"3628_CR48","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2022-074166","volume":"382","author":"KN Vokinger","year":"2023","unstructured":"Vokinger KN, Glaus CEG, Kesselheim AS, Serra-Burriel M, Ross JS, Hwang TJ (2023) Therapeutic value of first versus supplemental indications of drugs in US and Europe (2011\u201320): retrospective cohort study. BMJ 382:e074166","journal-title":"BMJ"},{"issue":"7624","key":"3628_CR49","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1136\/bmj.39281.615706.94","volume":"335","author":"S Garattini","year":"2007","unstructured":"Garattini S, Bertele V (2007) How can we regulate medicines better? BMJ 335(7624):803\u2013805","journal-title":"BMJ"},{"key":"3628_CR50","doi-asserted-by":"publisher","first-page":"1466","DOI":"10.1136\/bmj.p1466","volume":"382","author":"B Wieseler","year":"2023","unstructured":"Wieseler B (2023) Patients need better treatments, not just more of the same. BMJ 382:1466","journal-title":"BMJ"},{"issue":"10228","key":"3628_CR51","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1016\/S0140-6736(19)33178-2","volume":"395","author":"H Naci","year":"2020","unstructured":"Naci H, Salcher-Konrad M, Kesselheim AS et al (2020) Generating comparative evidence on new drugs and devices before approval. Lancet 395(10228):986\u2013997","journal-title":"Lancet"},{"issue":"7","key":"3628_CR52","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1016\/j.jclinepi.2014.12.016","volume":"68","author":"ME Flacco","year":"2015","unstructured":"Flacco ME, Manzoli L, Boccia S et al (2015) Head-to-head randomized trials are mostly industry sponsored and almost always favor the industry sponsor. J Clin Epidemiol 68(7):811\u2013820","journal-title":"J Clin Epidemiol"},{"key":"3628_CR53","doi-asserted-by":"crossref","unstructured":"West HJ (2023) Clinical decision making in the real world-the perfect as the enemy of the good. JAMA Oncol","DOI":"10.1001\/jamaoncol.2023.1811"},{"key":"3628_CR54","unstructured":"(EMA) EMA. Data analysis and real world interrogation network (DARWIN EU). https:\/\/www.ema.europa.eu\/en\/about-us\/how-we-work\/big-data\/data-analysis-real-world-interrogation-network-darwin-eu. Published 2023. Accessed 7 Aug 2023"},{"key":"3628_CR55","unstructured":"(FDA) USFDA. Real-world evidence. https:\/\/www.fda.gov\/science-research\/science-and-research-special-topics\/real-world-evidence. Published 2023. Updated 2 May 2023. Accessed 7 Aug 2023"},{"key":"3628_CR56","unstructured":"IQVIA (2023) Global oncology trends. https:\/\/www.iqvia.com\/insights\/the-iqvia-institute\/reports\/global-oncology-trends-2023. Published 2023. Updated 24 May 2023. Accessed 7 Aug 2023"},{"issue":"7","key":"3628_CR57","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1016\/S1470-2045(17)30415-1","volume":"18","author":"JC Del Paggio","year":"2017","unstructured":"Del Paggio JC, Sullivan R, Schrag D et al (2017) Delivery of meaningful cancer care: a retrospective cohort study assessing cost and benefit with the ASCO and ESMO frameworks. Lancet Oncol 18(7):887\u2013894","journal-title":"Lancet Oncol"},{"key":"3628_CR58","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.j4543","volume":"359","author":"D Cohen","year":"2017","unstructured":"Cohen D (2017) Cancer drugs: high price, uncertain value. BMJ 359:j4543","journal-title":"BMJ"},{"key":"3628_CR59","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2022-071710","volume":"380","author":"A Angelis","year":"2023","unstructured":"Angelis A, Polyakov R, Wouters OJ, Torreele E, McKee M (2023) High drug prices are not justified by industry\u2019s spending on research and development. BMJ 380:e071710","journal-title":"BMJ"}],"container-title":["European Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-024-03628-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00228-024-03628-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-024-03628-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,13]],"date-time":"2024-03-13T08:33:51Z","timestamp":1710318831000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00228-024-03628-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,20]]},"references-count":59,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,4]]}},"alternative-id":["3628"],"URL":"https:\/\/doi.org\/10.1007\/s00228-024-03628-2","relation":{},"ISSN":["0031-6970","1432-1041"],"issn-type":[{"type":"print","value":"0031-6970"},{"type":"electronic","value":"1432-1041"}],"subject":[],"published":{"date-parts":[[2024,1,20]]},"assertion":[{"value":"29 August 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 January 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 January 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Considering that our study relies upon data relating to previously published clinical trials and did Fnot require patient involvement, we did not solicit an opinion from the Hospital Ethics Committee nor did we require the collection of informed consent from patients.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}